DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pip... DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1. Show more
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic disease, today announced the closing of its...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered...
Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 Key Proof-of-Concept Results Expected in the First Half of 2025 Management will Host a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.155 | -3.65566037736 | 4.24 | 4.95 | 3.9836 | 78357 | 4.34605932 | CS |
4 | 0.105 | 2.63819095477 | 3.98 | 4.95 | 3.76 | 54433 | 4.19916414 | CS |
12 | 0.995 | 32.2006472492 | 3.09 | 4.95 | 2.65 | 55062 | 3.62700849 | CS |
26 | 1.225 | 42.8321678322 | 2.86 | 4.95 | 2.14 | 54555 | 3.22547355 | CS |
52 | 1.075 | 35.7142857143 | 3.01 | 4.95 | 1.9382 | 51096 | 2.95832292 | CS |
156 | 0.065 | 1.61691542289 | 4.02 | 4.95 | 1.12 | 82312 | 2.83162579 | CS |
260 | 1.305 | 46.9424460432 | 2.78 | 10.88 | 1.12 | 98758 | 4.34822434 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.